Edith Cowan University

Research Online
Research outputs 2014 to 2021
12-30-2021

Does androgen deprivation impact associations between
cognition and strength, fitness and function in communitydwelling men with prostate cancer? A cross-sectional study
Niamh L. Mundell
Patrick J. Owen
Jack Dalla Via
Edith Cowan University

Helen Macpherson
Robin M. Daly

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Medicine and Health Sciences Commons
10.1136/bmjopen-2021-058478
Mundell, N., Owen, P. J., Dalla Via, J., Macpherson, H., Daly, R., & Fraser, S. (2021). Does androgen deprivation
impact associations between cognition and strength, fitness and function in community-dwelling men with
prostate cancer? A cross-sectional study. BMJ open, 11(12), e058478.
https://doi.org/10.1136/bmjopen-2021-058478
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/11751

Authors
Niamh L. Mundell, Patrick J. Owen, Jack Dalla Via, Helen Macpherson, Robin M. Daly, and Steve F. Fraser

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/11751

Original research

Does androgen deprivation impact
associations between cognition and
strength, fitness and function in
community-dwelling men with prostate
cancer? A cross-sectional study
Niamh L Mundell  ,1 Patrick J Owen  ,1 Jack Dalla Via  ,1,2
Helen Macpherson  ,1 Robin M Daly  ,1 Steve F Fraser  1

To cite: Mundell NL, Owen PJ,
Dalla Via J, et al. Does
androgen deprivation impact
associations between cognition
and strength, fitness and
function in community-dwelling
men with prostate cancer? A
cross-sectional study. BMJ Open
2021;11:e058478. doi:10.1136/
bmjopen-2021-058478
► Prepublication history and
additional supplemental material
for this paper are available
online. To view these files,
please visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2021-058478).

Received 18 October 2021
Accepted 02 December 2021

© Author(s) (or their
employer(s)) 2021. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published by
BMJ.
1

Institute for Physical Activity
and Nutrition (IPAN), School of
Exercise and Nutrition Sciences,
Deakin University, Burwood,
Victoria, Australia
2
Institute for Nutrition Research,
School of Medical and Health
Sciences, Edith Cowan
University, Perth, Western
Australia, Australia
Correspondence to
Niamh L Mundell;
niamh.mundell@deakin.edu.a u

ABSTRACT
Objectives We investigated whether there were
differences in associations between cognition with muscle
strength, fitness and function in men with prostate cancer
(PCa) treated with, and without androgen deprivation
therapy (ADT) and non-PCa controls. A secondary aim
was to compare differences in the prevalence of cognitive
impairment.
Design This cross-sectional study compared 70 ADT-
treated men with PCa aged 50–85 years to non-ADT-
treated men (n=52) and non-PCa controls (n=70).
Setting University clinical exercise laboratory.
Interventions Nil.
Primary and secondary outcome
measures Standardised assessments were conducted for
cognition (learning, memory, attention, processing speed
and executive function), muscle strength (grip strength and
leg press), fitness (400 m walk), gait speed (4 m walk) and
dual-tasking mobility (timed-up-and-go with a cognitive
task).
Results ADT-treated men showed stronger associations
between fitness and executive function and task switching
relative to controls (both: p≤0.03). For both PCa groups
(independent of ADT use), poorer dual-task mobility was
more strongly associated with decreased psychomotor
attention (both: p≤0.027) and global cognitive function
(both: p≤0.031) compared with non-PCa controls. The
overall prevalence of cognitive impairment was low (4%–
13%) and did not differ between the groups.
Conclusions The presence of PCa, with or without ADT
treatment, did not increase the risk of cognitive impairment
relative to non-PCa controls, yet did alter the associations
between physical fitness and some measures of functional
performance with certain cognitive domains. This highlights
the importance of men with PCa maintaining fitness and
functional capacity to optimise cognitive health.
Trial registration number This study was registered with
the Australian and New Zealand Clinical Trials Registry
(ACTRN12614000317695).

INTRODUCTION
Prostate cancer (PCa) has the second highest
worldwide incidence of all male cancers (14%

Strengths and limitations of this study
► This study was strengthened by the use of a com-

►

►

►

►

prehensive battery of cognitive tests and a range of
physical outcomes that related to strength, fitness
and function.
A further strength was that we followed recent
guidelines from the International Cancer Cognition
Task Force with regards to defining cognitive
impairment
A limitation is that this study was a nested cross-
sectional substudy within a larger randomised
controlled trial, including exercise training and nutritional supplements for androgen deprivation therapy
(ADT)-treated men; hence, men treated with ADT
with a penchant for exercise may have been more
likely to participate.
Another limitation is that men on ADT recruited to
the study had all been treated for a minimum of
3 months; thus, we are unable to draw any conclusions in men who have recently commenced ADT
(ie, <3 months).
Finally, given the cross-sectional design, causality cannot be established between fitness, physical
function and certain cognitive domains with ADT.

in 2018), yet a high relative survival rate (8%
of cancer-related deaths).1 Androgen deprivation therapy (ADT) is a mainstay in the
treatment of appropriately selected men with
metastatic and non-
metastatic PCa.2 ADT
is associated with numerous adverse effects,
including cardiovascular and metabolic
complications, loss of lean (muscle) mass,3
increase in fat mass and impaired physical
performance, beyond that of natural ageing.4
Many ADT side effects may accelerate cognitive ageing, but evidence is inconclusive
regarding effects to risk of developing cognitive impairment.5 However, heterogeneity
in how cognitive impairment is defined and
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quantified has affected the degree to which cognitive
impairment has been detected and reported.6
ADT has been negatively associated with cognitive
performance in a range of domains, including reaction
time, spatial and verbal memory, visuomotor speed and
executive function, with the largest effects noted for
visuomotor function.7 Nevertheless, it has been difficult
to extricate the effects of PCa itself from those of ADT.
Androgens, such as testosterone, are proposed to support
male memory and visuospatial ability8 and may play a role
in maintaining hippocampal plasticity,9 yet the differential contributions of cognitive and motor abilities to
motor cognitive task performance are less clear.7 Declines
in visuomotor performance associated with ADT use may
be secondary to overall declines in motor function caused
by ADT, rather than a direct effect of androgen depletion on cognitive processes. To our knowledge, no studies
have evaluated the relationship between different cognitive domains reportedly affected by ADT and measures
of muscle strength, cardiorespiratory fitness and physical function (mobility) in men with PCa. Importantly,
the adverse effects of ADT on physical performance and
cognition may be amenable to intervention, thereby
reducing treatment-induced comorbidities from ADT.
The interdependence of physical and cognitive declines
during normal ageing is speculated to be bidirectional.10
Age-
related and disease-
related increases in inflammation, changes in hormonal production and signalling (eg,
insulin-like growth factor 1 (IGF-1) resistance, insulin-
receptor substrate 1 and growth hormone dysregulation) and cardiometabolic dysfunction, can all directly
contribute to both cognitive decline and muscle loss.11
There is also evidence that reduced muscle strength is
prognostic for cognitive status in older adults,12 and
declining muscle strength with age has been linked to an
increased risk of Alzheimer’s disease.13 Mobility impairments, particularly slow gait speed, have been associated
with poorer cognitive function in older adults.12 The
physiological mechanism(s) underlying this link between
muscle strength, physical function and cognition are not
completely clear. Skeletal muscle contractions upregulate various anti-
inflammatory myokines, neurotrophic
and growth factors that are important for neuroplasticity.14 Cardiorespiratory fitness may also protect against
precursors to cognitive impairment such as cerebrovascular, endothelial and neurological degeneration.15
Associations between muscle strength and function with
cognition have been identified in cancer survivors generally.16 However, whether reduced muscle strength, cardiorespiratory fitness and/or function are directly related
to poorer cognitive function in men with PCa-receiving
ADT is unknown.
Recent guidelines for measuring cognitive impairment in cancer research advocated the use of objective,
validated, domain-
specific measures and standardised
criteria.6 17 A variety of cognitive test batteries may be
incorporated; however, prior studies have varied in their
application and approach to analyses.18 Therefore, the
2

primary aim of this study was to determine the strength
and direction of any associations between muscle
strength, cardiorespiratory fitness and physical function
with cognitive function in men with PCa treated with and
without ADT and non-
PCa controls. A secondary aim
was to compare the prevalence of cognitive impairment
between men with PCa treated with and without ADT and
non-PCa controls using standardised test batteries.

MATERIALS AND METHODS
This study was a nested cross-sectional study embedded
alongside the baseline of a randomised controlled trial
designed to evaluate the combined effects of exercise–training and nutritional supplementation on
health outcomes in men with PCa treated with ADT.19
Recruitment of ADT-treated men was achieved via clinician referral from participating hospitals and support
groups and newspaper advertisements from April 2014
to November 2017. PCON and CON were recruited via
PCa support groups and newspaper advertisements from
October 2014 to February 2016.
Patient and public involvement
Participants were not involved in the development of
the research question, or design of the study. All participants were offered an individualised report outlining the
results of their assessment in comparison to population-
based norms. Additionally, ADT-treated men were eligible
to participate in a 12 month exercise and nutritional
intervention.19
Participants
A total of 70 men aged with PCa pharmacologically
treated with ADT for 12 weeks or greater (ADT), 52
men diagnosed with PCa not treated with ADT (prostate cancer control [PCON]) and 70 men not diagnosed
with PCa (control [CON]) were included in the study.
All men were aged 50–85 years. Exclusion criteria were:
(1) non-
English speaking; (2) any disorder known to
affect bone, calcium or vitamin D metabolism (other
than hypogonadism in the ADT group); (3) any current
pharmacological intervention known to affect bone
metabolism (other than ADT); (4) supplementation with
protein, calcium (>600 mg/day) or vitamin D (>1000 IU/
day) in the past 3 months; (5) current progressive resistance training (more than one session/week) or weight-
bearing impact exercises (>150 min/week) in the past
3 months; (6) current smokers; (7) weight greater than
159 kg; (8) plans to travel for longer than 6 weeks continuously within the following 52 weeks and (9) any absolute
contraindications to exercise training (eg, musculoskeletal, cardiovascular or neurological disorders) according
to the American College of Sports Medicine.
Measures
Standardised neurocognitive tests were used to assess
cognitive function, including domains shown to be
Mundell NL, et al. BMJ Open 2021;11:e058478. doi:10.1136/bmjopen-2021-058478
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sensitive to disease and treatment-
related changes in
patients with cancer (eg, learning and memory, processing
speed and executive function).6 This included the Trail
Making Test to assess visuomotor speed (TMTA), task
switching (TMTB) and executive function (TMTB minus
TMTA).20 Immediate recall, verbal learning and delayed
memory were assessed using the Rey Auditory Verbal
Learning Task (RAVLT, Rey auditory verbal learning test:
trial 1, trial 1–5 total, trial 7 respectively).21 The RAVLT
is a word list measure for immediate and delayed recall,
and verbal learning.21 Temporary verbal memory and
verbal working memory were assessed with the Digit-
Span test, which has also been validated in patients with
cancer.22 The National Adult Reading Test was included
to provide an estimate of cognitive reserve 6, rather than
as a measure proposed to be influenced by ADT.
The CogState Computerised Battery (CCB) (CogState,
Melbourne, Australia) was also included to assess cognition, and has been customised and validated for patients
with cancer.22 23 Briefly, participants completed five tests
that included game-
like stimuli such as playing cards
and tasks that measure a range of different cognitive
domains: (1) Groton Maze Learning Test (GMT)—executive function, (2) detection task (DET)—processing
speed and simple reaction time, (3) identification task
(IDN)—choice reaction time and visual attention, (4)
one card learning task (OCL)—attention and visual
learning and (5) one back task (ONB)—working memory
and visuomotor speed.23 Written and verbal instructions
were given and a practice trial undertaken prior to each
test. Outcomes were obtained for measures of reaction
time of correct responses (in milliseconds) (IDN, DET,
ONB), proportion of correct responses (OCL) and total
number of errors on five consecutive trials at a single
session (GMT). The IDN, DET and ONB reaction time
scores were log10 transformed, while the square root of
the proportion of correct responses on the OCL task was
arcsine transformed.24 These subtests were used to calculate raw scores, from which z-scores were derived using
the mean and SD of the total sample.25 Three composite
scores were calculated by averaging z-scores from specific
tests: (1) global cognition (DET, IDN and OCL); (2)
psychomotor-attention composite (DET and IDN), and
(3) working-memory and learning composite (OCL and
ONB).25 Higher composite scores represent better overall
cognitive function.
We used two approaches to determine cognitive impairment (CI). Both approaches align with the International
Cancer Cognition Task Force (ICCTF) proposed guidelines for assessing cognitive function in patients with
cancer.26 The first method (standard battery (SB)) was
based on scores 2-SD below the sample mean on at least
two of eight tests from the TMT (TMTA, TMTB, TMTB-
TMTA), digit span and RAVLT tests (trials 1, 1–5, 7, DS
forward, DS backwards).6 17 The second method used
five cognitive domains from the CCB: psychomotor
function/processing speed (detection), attention (identification), working memory (one-back), visual memory
Mundell NL, et al. BMJ Open 2021;11:e058478. doi:10.1136/bmjopen-2021-058478

(one-card-learning) and executive function errors (the
GMT). For this method, CI was indicated by a z score
−1.0 SD or below the sample mean on three of the five
tests.17 Both of these approaches are conservative selections within the range of appropriate test batteries
possible under the ICCTF criteria, with the probability
of exceeding cut-off criteria by chance p≤0.015 to ≤0.032,
respectively.27
As previously reported,19 lower limb muscle strength
(kg) was measured using a three repetition maximum
(3-
RM) protocol (leg press, Synergy Omni Leg Press
S-
31OPD, Yatala, QLD, Australia) while upper limb
strength was assessed using grip strength (Jamar Plus
Digital, Lafayette Instrument Company, IN, USA), with the
highest score (kg) of three attempts from either the left
or right hand recorded. Dual-task mobility was measured
using the timed-up-and-go test with an additional cognitive task (DT TUG) using methods described previously.19 The time to complete the test was recorded with
a stopwatch. Number of correct digits was also recorded;
however, studies in non-cancer adults have indicated that
an increase in cognitive load while dual tasking produces
a trade-off effect to gait speed, regardless of the degree of
difficulty of the cognitive task.28 Therefore, the DT TUG
speed (sec) was used as an indication of physical performance (mobility) under cognitive load. Gait speed and
estimated cardiorespiratory fitness were measured with
the 4 m usual walk test and 400 m walk test, respectively.29
Resting blood pressure was calculated after an initial
10 min, seated rest using the means of the final two of
three measurements taken by an automatic sphygmomanometer (TM-2655P, A&D, Tokyo, Japan).30 Height was
measured using a stadiometer to the closest 0.1 cm, (220,
Seca, Hamburg, Germany). Body mass was be measured
using electronic scales (UC-321, A&D, Tokyo, Japan) to
the closest 0.1 kg. Body mass index (BMI) was calculated
to the closest 0.1 kg/m2.
A questionnaire incorporating demographics, lifestyle
and clinical information was used to obtain specific age,
education, comorbidities, alcohol intake, PCa status and
treatment details. Any discrepancies or queries with prior
treatment details were resolved by checking medical
records supplied by participants, or by their referring
clinician. The Community Healthy Activities Model
Programme for Seniors physical activity questionnaire
was used to determine participation in a broad list of low,
moderate and vigorous physical activities, with moderate-
vigorous physical activity (kJ per week) reported.31 The
Depression Anxiety and Stress Scale was used to provide a
measure of depression, anxiety, stress and general psychological distress, all of which have been shown to be altered
by PCa diagnosis.32
Data analysis
All analyses were performed using Stata statistical software V.15 (StataCorp, College Station, Texas). Normality
of the distribution of residuals was assessed visually via
quantile–quantile plots and histograms. Between-group
3
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comparisons of participant characteristics were assessed
by χ2 tests for categorical variables and analyses of variance for continuous variables. The strength and direction of associations between cognitive outcomes and
measures of muscle strength, cardiorespiratory fitness
and function were first assessed using Pearson’s correlation coefficient in each group of men separately and all
men combined. Analyses of covariance was then used to
compare regression line slopes between groups for significant correlations between measures of muscle strength,
cardiorespiratory fitness and function with cognitive function. To reduce the risk of type II error due to multiple
comparisons, post hoc analyses applied the Tukey test. If
no differences in slopes were identified, intercepts were
compared between groups assuming identical slopes.33
An alpha level of <0.05 was adopted for all statistical tests.
RESULTS
Participant characteristics of each group are presented
in table 1. The mean (SD age of the total sample was 70
(7) years. Median (range) ADT duration was 12 (3–166)
months. The treatment methods for ADT were as follows:
goserelin (n=40, 57.1%), leuprorelin (n=14, 20%), goserelin and bicalutamide (n=5, 7.1%), leuprorelin and bicalutamide (n=3, 4.3%), triptorelin (n=3, 4.3%), degarelix
(n=2, 2.9%), abiraterone (n=1, 1.4%), degarelix and
bicalutamide (n=1, 1.4%) and enzalutamide (n=1, 1.4%).
Stage of PCa differed between ADT and PCON, with
approximately two-thirds (64%) of the former having had
localised PCa (with or without previous prostatectomy)
and most (85%) of the latter unsure of PCa stage. On
average, ADT had a higher BMI than PCON (mean difference, 2.2 kg/m2, p=0.010), but not CON. Men treated
with ADT had 9.5% (p=0.003) and 13% (p<0.001) lower
grip strength compared with PCON and CON, respectively. The 400 m walk test took 4.0% (p=0.002) and 8.0%
(p<0.001) longer for the ADT compared with PCON and
CON, respectively. PCON participants had fewer anxiety
symptoms than CON (p=0.007), but not ADT (p=0.060).
There was no significance between-group differences for
alcohol consumption, total/cardiometabolic comorbidities, IQ, highest level of schooling or depressive/anxiety/
stress symptomatology.
Comparisons of cognitive function across the three
groups are shown in table 2. On average, ADT had 17%
and 13% slower visuomotor speed (TMTA) than PCON
(p=0.011) and CON (p=0.042), respectively. Both ADT
and PCON had 0.5 SD (p=0.003) to 0.7 SD (p<0.001)
slower simple reaction time (DET) and 0.4 SD (p=0.035)
to 0.6 SD (p=0.001) slower choice reaction time when
compared with CON. Choice reaction time (IDN) was
also 0.4 SD to 0.6 SD slower in ADT (p=0.035) and
PCON (p=0.001) compared with CON. Psychomotor-
attention composite scores (Cogstate) were lower in both
ADT (−0.4 SD, p=0.006) and PCON (−0.6 SD, p<0.001)
compared with CON. Finally, global cognition was lower
in PCON (−0.3 SD, p=0.019) with a trend for ADT (−0.3
4

SD, p=0.073), compared with CON. Notably, in further
analyses that adjusted for obesity and anxiety, the only
difference to the initial analyses was that working memory
speed in ADT was slower compared with PCON (p=0.006),
with no change to any other results.
Associations between muscle strength, cardiorespiratory fitness and physical function with cognition for each
of the three groups separately are shown in table 3. For
leg press and grip strength, there were little or no associations with the RAVLT or digit span cognitive measures
in any of the groups. In contrast, there were a number of
significant correlations in each group between these two
measures of muscle strength with the TMT and Cogstate
composite cognitive outcomes (table 3), indicating that
greater muscle strength was associated with better cognitive performance. However, when these associations were
compared between groups, there were no group differences in the strength (slope) of the muscle strength to
cognition relationships (online supplemental figure 1).
Pooled data showed that when all men were combined,
there were a number of significant associations between
measures of lower and upper limb strength with several
cognitive domains (online supplemental table 1)
The associations between physical function and cardiorespiratory fitness with cognition by group are shown
in table 3. For gait speed, there were little or no associations with any of the cognitive measures in any of the
groups. In contrast, there were a number of significant
relationships within each of the groups between cardiorespiratory fitness and DT TUG with various cognitive
measures. Specifically, the findings indicate that a greater
level of fitness and dual task mobility were associated with
better cognitive function across a number of domains for
all. When these associations were compared between the
three groups of men, the following significant differences
in the slope were identified: (a) poorer cardiorespiratory
fitness (slower 400 m walk time) was more strongly associated with a worse task switching performance (TMTB)
in ADT compared with both PCON (p=0.018) and CON
(p=0.032) (figure 1A), (b) poorer cardiorespiratory
fitness was more strongly associated with a worse executive function (TMTB-A) in ADT when compared with
PCON (p=0.009) and CON (p=0.037) (figure 1B), (c)
slower dual task mobility (DT TUG) was more strongly
associated with a worse psychomotor-attention composite
scores in both ADT (p=0.027) and PCON (p=0.012) relative to CON (figure 2A), (d) slower dual task mobility
was more strongly related to a worse working-memory
and learning composite scores in ADT compared with
CON (p=0.006), and to a lesser degree PCON (p=0.051)
(figure 2B), (e) slower dual task mobility was more
strongly associated with a worse global cognition in both
ADT (p=0.001) and PCON (p=0.031) relative to CON
(figure 2C); (f) slower dual task mobility was similarly associated with poorer performance in tests of task switching
(figure 3A) and executive function (figure 3B) for all
groups. However, comparison of the intercepts revealed
that for a given dual task mobility time, ADT performed
Mundell NL, et al. BMJ Open 2021;11:e058478. doi:10.1136/bmjopen-2021-058478
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Table 1 Characteristics of men with prostate cancer treated with androgen deprivation therapy (ADT), prostate cancer
controls (PCON) and non-PCA controls (CON)
Variable

ADT

PCON

CON

P-value

N
Age, year

70
71±6

52
69±6

70
69±7

0.072

 Localised/removed

45 (64.3)

6 (11.1)

–

 Advanced

5 (7.1)

2 (3.7)

–

 Unknown

20 (28.6)

44 (84.6)

–

Stage of prostate cancer, n (%)
<0.001

Previous prostatectomy, n (%)*

34 (48.6)

36 (69.2)

–

0.022

Previous radiotherapy, n (%)*

48 (68.6)

12 (23.1)

–

<0.001

Previous chemotherapy, n (%)*

11 (15.7)

0 (0.0)

–

Active surveillance, n (%)

–

8 (15.4)

–

Weight, kg

85.5±17.1

82.4±13.5

85.1±14.7

2

0.003
–
0.073

Body mass index, kg/m

28.8±5.1

26.6±4.0

27.5±3.1

0.013

 Normal, n (%)

12 (17.1)

24 (46.2)

15 (21.4)

0.003

 Overweight, n (%)

37 (52.9)

19 (36.5)

41 (58.6)

 Obese, n (%)

21 (30.0)

9 (17.3)

14 (20.0)

Alcohol consumption, n (%)

32 (53.3)

16 (32.7)

32 (45.7)

0.095

 If yes, g/d

25±20

15±10

23±19

0.190

Total comorbidities,† n

2±2

2±2

2±1

0.449

Cardiometabolic comorbidities,‡ n

1±1

1±1

1±1

0.354

 Hypertension, n (%)

32 (45.7)

20 (38.5)

24 (34.3)

0.377

 Heart disease, n (%)

20 (28.6)

7 (13.5)

20 (28.6)

0.096

 Hypercholesterolaemia, n (%)

27 (38.6)

17 (32.7)

26 (37.1)

0.792

 Type 2 diabetes, n (%)

7 (10.0)

5 (9.6)

4 (5.7)

0.608

IQ points

117±5

115±5

116±5

0.253

5 (7.1)

3 (5.8)

8 (11.4)

0.198

 Completed high school, n (%)

11 (15.7)

3 (5.8)

7 (10.0)

 Tech/trade certificate, n (%)

12 (17.2)

17 (32.7)

12 (17.1)

 Tertiary, n (%)

42 (60.0)

29 (55.7)

43 (61.5)

Depressive symptoms, n (%)

10 (16.1)

9 (17.3)

14 (20.0)

0.838

 Normal, n (%)

52 (83.9)

43 (82.7)

56 (80.0)

0.602

 Mild, n (%)

6 (9.7)

2 (3.9)

3 (4.3)

 Moderate, n (%)

2 (3.2)

5 (9.6)

6 (8.6)

 Severe, n (%)

0 (0.0)

1 (1.9)

2 (2.8)

 Extremely severe, n (%)

2 (3.2)

1 (1.9)

3 (4.3)

Anxiety symptoms, n (%)

14 (22.6)

5 (9.6)

21 (30.0)

0.026

 Normal, n (%)

48 (77.4)

47 (90.4)

49 (70.0)

0.205

 Mild, n (%)

5 (8.1)

3 (5.8)

8 (11.4)

 Moderate, n (%)

5 (8.1)

0 (0.0)

5 (7.2)

 Severe, n (%)

3 (4.8)

2 (3.8)

4 (5.7)

 Extremely severe, n (%)
Stress symptoms, n (%)

1 (1.6)
18 (29.0)

0 (0.0)
13 (25.0)

4 (5.7)
25 (35.7)

Highest level of schooling
 Some high school, n (%)

0.426
Continued
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Table 1 Continued
Variable

ADT

PCON

CON

P-value

 Normal, n (%)

44 (71.0)

39 (75.0)

45 (64.3)

 Mild, n (%)

3 (4.8)

5 (9.6)

9 (12.9)

 Moderate, n (%)

10 (16.2)

5 (9.6)

6 (8.6)

 Severe, n (%)

3 (4.8)

3 (5.8)

5 (7.1)

 Extremely severe, n (%)

2 (3.2)

0 (0.0)

5 (7.1)

 Leg press, kg

139.7±46.9

143.5±42.0

160.3±49.5

 Grip strength, kg

37.9±6.5

41.7±6.7

43.3±8.0

<0.001

 Gait speed, m/sec

1.42±0.21

1.48±0.19

1.50±0.22

0.089

 DT TUG, sec
 400 m walk, sec

11.33±3.90
287.25±38.4

11.64±4.58
275.92±32.0

11.49±4.97
265.10±41.70

0.933
0.004

0.338

Muscle strength
0.048

Physical function and fitness

Data are mean±SD or number (percentage) within group. DT-TUG, dual task timed-up-and-go.
*ADT versus PCON only.
†Respiratory/pulmonary diseases, musculoskeletal, neurological, or immunological conditions.
‡Hypertension, type 2 diabetes, heart disease, hypercholesterolaemia.

more poorly on the task-switching test (TMTB intercept
p=0.031) and executive function test (TMTB-A intercept
p=0.037) compared with CON only. There were no other
significant differences in slopes or intercepts between the
groups (online supplemental figure 2).
Overall, nine (13%) ADT men, two (3.9%) PCON
and seven (10%) CON demonstrated cognitive impairment using the standard battery (figure 4A). In contrast,
four (5.7%) ADT men, five (9.6%) PCON and four
(5.7%) CON had cognitive impairment using the CCB
(figure 4B). The prevalence of cognitive impairment did
not differ significantly between the three groups for the
standard battery (p=0.234) or CCB (p=0.633).
DISCUSSION
The main finding from this study was that PCa, with and
without ADT treatment, appears to alter the association
between physical function and fitness (but not muscle
strength), with various measures of cognitive function.
For ADT-treated men specifically, stronger associations
were evident between cardiorespiratory fitness and task
switching ability and between cardiorespiratory fitness
and executive function compared with both controls,
indicating a stronger link between poorer fitness and
reduced cognition in the ADT-treated men. Additionally,
in both ADT and non-ADT men with PCa compared with
CON, there were stronger inverse associations between
dual-task mobility and psychomotor attention as well as
dual-
task mobility and global cognition. However, the
overall prevalence of cognitive impairment based on
established criteria was relatively low and similar for men
with PCa treated with and without ADT (4%–13%), and
no different from controls (6%–10%), although ADT-
treated men had 17% and 13% lower visuomotor speed
6

compared with PCON (p=0.011) and CON (p=0.042),
respectively.
Previous research has shown that ADT use is associated
with a deterioration in muscle strength, cardiorespiratory fitness and functional performance.3 4 In non-PCa
lower muscle strength, fitness and function are linked
to reduced cognitive function.34 Our study is the first to
show that the relationship between some of these physical measures and cognitive function differs between
ADT-treated men relative to PCa and/or CON. A causal
association cannot be established between cardiorespiratory fitness and both task-switching ability and executive
function. However, these outcomes offer insight into the
previously reported mixed findings reported in prior
research regarding the effects of ADT versus non-ADT
on cognition in men with PCa.6 35 These adverse effects
are supported by data showing that lower testosterone
concentrations are associated with lower fitness and function36 as well as deficits in memory37 and greater risk for
induced
Alzheimer’s disease.38 It is possible that ADT-
hypogonadism may accelerate age-
related declines in
brain processes, contributing in part to deteriorations in
certain cognitive domains (eg, memory and visuospatial
function).8 ADT-induced losses in cardiovascular fitness
and function6 39 may also have secondary effects to cognition, creating a bidirectional and compound association.
An interesting finding from this study was that muscle
strength was significantly lower in ADT-
treated men
compared with controls, but any associations between leg
press muscle strength or grip strength with the various
cognitive measures were either not significant or mixed
across the three groups. This suggests that the ADT
group had lower muscle strength, and while ageing may
affect the association,10 PCa, with or without ADT, does
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6 (2)
40 (10)
8 (3)

Rey Auditory Verbal Learning Test, n
 Immediate recall

 Verbal learning

 Delayed recall

45.4 (45.5)

0.0 (0.8)
−0.1 (0.7)

 Working memory learning
 Global cognition

0.0 (0.7)
−0.1 (0.6)

0.0 (0.8)
0.2 (0.7)

0.3 (0.8)

39.2 (25.7)

70.3 (32.0)

31.1 (10.9)

7 (3)

11 (3)

8 (3)

42 (10)

5 (1)

CON

0.952
0.049

0.001

0.289

0.107

0.021

0.536

0.930

0.885

0.608

0.564

P-value

0.0 (−0.3, 0.3)
0.0 (−0.2, 0.3)

0.2 (−0.1, 0.5)

9.6 (−2.7, 21.9)

15.2 (0.5, 29.8)

5.6 (1.4, 9.8)*

1 (−1, 1)

0 (−1, 1)

0 (−1, 1)

0 (−4, 4)

0 (−1, 0)

0.0 (−0.3, 0.2)
−0.3 (−0.4, 0.0)

−0.4 (−0.7,–0.1)**

6.2 (−5.2, 17.5)

10.5 (−3.0, 24.0)

4.4 (0.5, 8.2)*

0 (−1, 1)

0 (−1, 1)

0 (−1, 1)

−2 (−5, 2)

1 (0, 1)

ADT versus PCON ADT versus CON

Unadjusted mean difference (95% CI)

0.0 (−0.3, 0.2)
−0.3 (−0.5, 0.0)*

−0.6 (−0.9,–0.3)***

−3.5 (−15.2, 8.6)

−4.7 (−18.8, 9.4)

−1.2 (−5.3, 2.8)

−1 (−1, 0)

0 (−1, 1)

0 (−2, 1)

−2 (−6, 2)

1 (0, 1)

PCON versus
CON

Data are unadjusted mean (SD) and unadjusted mean difference (95% CI). *p<0.05, **p<0.01, ***p<0.001. Visuomotor speed (Trail making Test part A), Task Switching (Trail making Test part
B), Executive Function (Trail making Test part B-A); Immediate recall (Rey Auditory Verbal Learning Test (RAVLT) trial 1); Verbal learning (RAVLT trial 1–5 inclusive); Delayed recall (RAVLT trial
7); Verbal temporary memory (Digit Span forwards); Verbal working memory (Digit Span backward). CogState measures: Simple reaction time (DET speed); Choice reaction time (IND speed);
Working memory speed (ONB speed), Working memory accuracy (ONB accuracy), Visuospatial executive function (GML errors); Psychomotor-attention (DET and IDN); Working-memory and
learning (OCL and ONB), Global cognition (DET, IDN, and OCL).

−0.1 (0.9)

 Psychomotor-attention

CogState composite scores
−0.3 (0.9)

35.8 (18.8)

80.8 (53.5)

 Task switching

 Executive function

65.7 (22.5)

35.5 (13.0)

29.9 (8.5)

6 (2)

11 (2)

8 (3)

40 (9)

6 (1)

PCON

 Visuomotor speed

Trail making test, sec

11 (3)
7 (2)

 Verbal temporary memory

 Verbal working memory

Digit span, n

ADT

Variable

Unadjusted mean (SD)

Table 2 Mean scores for the individual cognitive tests and CogState composite Z-scores for men with prostate cancer treated with androgen deprivation therapy (ADT;
n=70), prostate cancer controls (PCON; n=52) and non-PCA controls (CON; n=70) and the mean unadjusted differences between the groups
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Table 3 The associations between muscle strength and function and different measures of cognition in men with prostate
cancer treated with androgen deprivation therapy (ADT; n=70), prostate cancer controls (PCON; n=52) and non-PCA controls
(CON; n=70)
Variable

Leg press 3RM

Rey Auditory Verbal Learning Test
Immediate recall
ADT

Verbal learning

Delayed recall

Grip strength

Gait speed

400 m walk

TUGC
−0.212

0.24

0.083

0.144

−0.268*

PCON

0.073

−0.029

0.299

−0.354*

−0.428**

CON

0.23

0.239

0.087

−0.346**

−0.232

ADT

0.071

0.077

0.122

−0.284*

−0.310*

PCON

0.169

−0.032

CON

0.259

0.261

−0.287

−0.374*

0.257*

0.191***

−0.458**

−0.247

ADT

−0.013

0.054

0.076

−0.245

−0.247

PCON

−0.099

−0.097

0.173

−0.266

−0.322*

CON

0.183

0.231

0.179

−0.359**

−0.08

ADT

0.169

0.199

0.157

−0.341*

−0.241

PCON

0.087

0.111

0.021

−0.029

−0.253

Digit span
Temporary verbal memory

Verbal working memory

CON

0.158

0.071

0.204

−0.334**

−0.288*

ADT

−0.051

0.038

0.097

−0.028

−0.275*

PCON

0.368*

0.148

0.309*

−0.195

−0.349*

CON

0.108

0.132

0.209

−0.208

−0.155

ADT

−0.179

−0.172

−0.267*

0.372**

0.329*

PCON

−0.206*

−0.016

−0.269

0.400**

0.399**

Trail making test
Visuomotor speed

Task switching

Executive function

CON

−0.446***

−0.313**

−0.275*

0.282*

0.217

ADT

−0.225

−0.259*

−0.196

0.403**

0.347**

PCON

−0.357*

−0.001

−0.133

0.172

0.358*

CON

−0.483***

−0.262*

−0.146

0.330**

0.212

ADT

−0.215

−0.255

−0.154

0.370**

0.313*

PCON

−0.321

0.006

−0.038

0.026

0.249

CON

−0.416**

−0.194

−0.065

0.292*

0.172

CogState composite scores
Psychomotor-attention

Working memory learning

Global cognition

ADT

0.261

0.307*

0.193

−0.176

−0.389**

PCON

0.069

0.213

0.287*

−0.205

−0.473***

CON

0.358**

0.317**

0.1

−0.235

−0.073

ADT

0.264

0.126

0.146

−0.144

−0.467***

PCON

0.179

−0.006

0.066

−0.136

−0.228

CON

0.303*

0.382**

0.132

−0.237

−0.098

ADT

0.313*

0.254*

0.209

−0.289*

−0.522***

PCON
CON

0.174
0.402**

0.162
0.444***

0.248
0.155

−0.23
−0.294*

−0.491***
−0.099

Data are Pearson’s correlation coefficient adjusted for multiple comparisons using Tukey’s test. *p<0.05, **p<0.01, ***p<0.001 (bold).
Visuomotor speed (Trail making Test part A), task switching (Trail making Test part B), executive function (Trail making Test part B-A);
immediate recall (Rey Auditory Verbal Learning Test (RAVLT) trial 1); verbal learning (RAVLT trial 1–5 inclusive); delayed recall (RAVLT trial 7);
verbal temporary memory (Digit Span forwards); verbal working memory (Digit Span backward). CogState measures: Simple reaction time
(DET speed); choice reaction time (IND speed); working memory speed (ONB speed), working memory accuracy (ONB accuracy), visuospatial
executive function (GML errors); psychomotor attention (DET and IDN); working memory and learning (OCL and ONB), global cognition (DET,
IDN, and OCL).
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Figure 1 Scatterplots of the relationship between
cardiorespiratory fitness (400 m walk test performance) with
task switching (trail making test B; A) and executive function
(trail making test B-A; B) in men treated with androgen
deprivation therapy (ADT), prostate cancer controls (PCON)
and non-PCA controls (CON). Slope differences: *p<0.05
compared with PCON, ˆ p<0.05 compared with CON.

not alter the degree to which strength impacts cognition.
Mechanistically, muscle contractions can stimulate an
increase in circulating brain-derived neurotrophic factor
(BDNF), which is used for peripheral muscle metabolic
processes.14 With regards to central cognitive processes,
BDNF is thought to partially compensate for testosterone-
mediated plasticity in testosterone depletion.40 However,
permeability of muscle-derived BDNF across the blood-
brain barrier is uncertain;14 therefore, peripheral muscle
contractions are less likely to be relevant to cognition
with or without ADT. By contrast, cardiorespiratory
exercise is associated with increased circulating vascular
and endothelial growth factors (eg, IGF-1), which may
directly upregulate hippocampal BDNF,14 theoretically
facilitating hippocampal synaptic plasticity in the absence
of testosterone. Thus, those with greater strength may
not necessarily benefit cognitively in the context of
androgen depletion, but greater cardiorespiratory fitness
may stimulate hippocampal BDNF and, thereby, partially
compensate for a cognitive disadvantage with androgen

Figure 3 Scatterplot of the relationship between dual-task
mobility (timed-up-and-go with cognitive task) with task
switching (trail making test B; A) and executive function (trail
making test B-A; B) in men treated with androgen deprivation
therapy (ADT), prostate cancer controls (PCON) and non-PCA
controls (CON). Since there were no differences in the slope,
the regression lines assume identical slopes but there were
between group differences in the intercepts: ˆp<0.05 intercept
difference compared with CON.

deficiency. As methods of measuring hippocampal BDNF
in humans evolve, related future studies may consider,
including such a measure.
Testosterone depletion has been linked with dementia
risk and AD, and prior research has suggested a role of
ADT in progression to AD and dementia.26 It is worth
noting that compromised cardiometabolic health
increases the risk of neurocognitive impairment, and
imaging studies have demonstrated that patients on ADT
show reduced functional connectivity in brain structures
(which may be vulnerable to vascular risk) associated with
reaction time, attention, memory, information processing
and spatial awareness.41 42 ADT promotes artherogenesis and is associated with compromised cardiovascular
health.3 39 In the current study, matching samples based
solely on age may have contributed to between-group
differences in demographic characteristics; however;
analysis of participant characteristics did not identify any
between-
group difference in habitual physical activity

Figure 2 Scatterplots of the relationship between dual-task mobility (timed-up-and-go with cognitive task) with Cogstate
psychomotor-attention composite score (A), Cogstate working memory-learning composite score (B) and Cogstate global
cognitive function score (panel C) in men treated with androgen deprivation therapy (ADT), prostate cancer controls (PCON) and
non-PCA controls (CON). Slope differences: ˆp<0.05 compared with CON.
Mundell NL, et al. BMJ Open 2021;11:e058478. doi:10.1136/bmjopen-2021-058478

9

BMJ Open: first published as 10.1136/bmjopen-2021-058478 on 30 December 2021. Downloaded from http://bmjopen.bmj.com/ on February 27, 2022 at Edith Cowan University. Protected
by copyright.

Open access

Figure 4 The prevalence of cognitive impairment in men treated with androgen deprivation therapy (ADT), prostate cancer
controls (PCON) and non-PCA controls (CON) using the standard battery (A) consisting of the trail making test, Rey auditory
verbal learning test and digit span, and the Cogstate computerised battery (B) consisting of the Groton maze learning test,
detection task, identification task, one card learning task and one back task. -No cognitive impairment; -cognitive
impairment.

levels or the number of comorbid conditions (including
hypertension, type 2 diabetes, heart disease, hypercholesterolemia, respiratory/pulmonary diseases, musculoskeletal, neurological or immunological conditions).
In addition, in an exploratory analysis when further
adjustments were made to account for between-group
differences in BMI and anxiety, results were unchanged.
However, subclinical levels of cardiometabolic dysfunction have been identified in adults prior to clinical manifestation of disease.41 Changes to cardiometabolic health
that have not reached clinically detectable levels (eg,
subclinical atherosclerosis, arterial stiffness, endothelial
dysfunction)41 are less likely with increased cardiorespiratory fitness.39 These changes may be present in ADT men
to a greater degree than for controls. Alternatively, the
between-group differences in association between cardiorespiratory fitness and cognitive function may be due
to the combined effects of testosterone suppression on
neuroplasticity and cardiometabolic health, rather than a
direct effect of ADT per se.
Another key finding from this study was the motor–
cognitive associations observed in both groups of men
with PCa, indicating that this relationship cannot be
attributable solely to testosterone suppression. Furthermore, reaction time and psychomotor attention deficits
were apparent in all men with PCa regardless of whether
they received ADT. The dual-task mobility test comprised
multiple motor components (lower limb power, initiation of stepping, acceleration, deceleration, turning
ability) and has been linked with executive function and
early detection of functional decline in older adults.43
This study did not measure serum hormones; however,
elevated serum IGF-1 has been identified as a marker
PCa risk, and serum IGF-
1 suppression is a common
target of cancer treatments.44 IGF-1 also plays an anabolic
role in tissue regeneration and cerebral neuromodulation (facilitated by exercise), and age-
related declines
in serum IGF-1 may contribute to declines in cognitive
and motor function for men with PCa.44 Thus, any cancer
treatment that impacts IGF-
1 may impact motor and
10

cognitive function, which may explain an effect on cognition in PCa patients,45 thereby affecting both ADT and
PCON to varying degrees. Future studies in men with PCa
may consider the potential for endocrine and hormonal
contributions to motor–cognitive associations for men
with PCa. In addition, the merits of cardiorespiratory and
multimodal exercise training in men with PCa are worth
investigation, as these have shown benefits to function,
cardiometabolic and cognitive health in older adults.46
This study did not identify any between-group differences in the prevalence of cognitive impairment using
recommended criteria. Comparisons to prior studies are
difficult as these studies have often yielded inconsistent
findings,6 but an estimated 47%–69% of men with PCa
treated with ADT have cognitive deficits in at least one
domain over 6–12 months.46 These mixed findings are
likely due to heterogeneous methodology, varying definitions of cognitive impairment and inconsistent use of
objective, sensitive, validated tests (eg, an Auditory Verbal
Learning Test, Digit Span and TMT).6 7 There are few
studies using recommended criteria,18 and to our knowledge, none in ADT-treated men, which adjust for multiple
comparisons in cognitive test batteries (as the number of
cognitive tests used increases, the number of SD from
the norm required for an abnormal classification should
decrease proportionally).17 A prospective study observing
ICCTF criteria (and adjusting for multiple comparisons)
assessed objective cognitive performance in men with
PCa (n=58) with ADT and having had prostatectomy
only.47 This study found that men receiving ADT for a
period of 6 or 12 months were 70% and 50%, respectively,
more likely to demonstrate an impaired performance in
executive function than controls, but based on the ICCTF
criteria, cognitive impairment did not differ across
groups.47 Our study also showed that the clinical utility of
the two batteries used to determine cognitive impairment
are comparable in this patient population. According to
these criteria, there were no significant differences in
cognitive impairment between ADT-
treated men, PCa
controls and CON in our study. It is possible that this
Mundell NL, et al. BMJ Open 2021;11:e058478. doi:10.1136/bmjopen-2021-058478
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finding is due to a recruitment bias inherent in the larger
study. Men recruited for this study were offered a free
‘health assessment’, which may have led to an inclination
for more health-focussed individuals to volunteer, biased
participation towards individuals with healthy lifestyles
and less chronic disease.48 In addition, batteries selected
were highly specific (SB: p≤0.015, CCB: p≤0.032).17 27 We
also adjusted for multiple comparisons, therefore may
have underestimated the prevalence of an abnormal
result in any one test. Although our study did not identify
a difference in the overall prevalence of cognitive impairment, across the specific cognitive domains, we identified
deficits in visuomotor function (TMTA) in men treated
with ADT compared with both controls. Consistent with
our findings of a moderate effect of ADT on visuomotor
function compared with non-
ADT PCa (g=−0.50) and
CON (g=−0.36), a previous meta-analysis also reported
a moderate effect size49 of ADT on visuomotor function
(g=−0.67, p=0.008).7 The visuomotor TMTA measure
relies on integration of executive and fine-motor control
of the upper limb and hand for visuomotor coordination.50 The absence of significant comparative deficits in
other cognitive measures such as executive function (eg,
TMTB-TMTA) in the ADT-treated men suggests that the
impairment may be attributed to reduced motor capabilities rather than loss of executive control.
To our knowledge, this is the first study to assess the
association between muscle strength, fitness and physical
function with cognition in ADT-treated men compared
with other patients with PCa not on ADT and healthy
controls. A strength of this research is that it included a
comprehensive battery of cognitive tests and a range of
physical outcomes that related to strength, fitness and
function. It also followed recent guidelines from the
ICCTF with regards to defining cognitive impairment.6
Our study does contain limitations, which should be
considered when interpreting results. First, this study
was a nested cross-
sectional substudy within a larger
randomised controlled trial, including exercise training
and nutritional supplements for ADT-treated men.19 Men
on ADT recruited to the study had all been treated for
a minimum of 3 months; however, adjusting for duration of treatment did not alter results. Second, there
were differences in PCa stage between ADT and PCON,
and a marked proportion (85%) of PCON did not know
the stage of their PCa. Finally, although causal direction
cannot be established between fitness, physical function
and certain cognitive domains with ADT, these findings support the maintenance of fitness and functional
capacity for cognitive health in men with PCa.
In summary, reduced cardiorespiratory fitness, but
not muscle strength, was associated with compromised
cognitive function in men with PCa treated with ADT
compared with controls. Additionally, dual-task mobility
was associated with the psychomotor-attention composite
and global cognition in men with PCa overall compared
with controls. ADT-
treated men showed significantly
slower visuomotor speed compared with both controls;
Mundell NL, et al. BMJ Open 2021;11:e058478. doi:10.1136/bmjopen-2021-058478

however, ADT did not alter prevalence of cognitive
impairment overall. This is the first study to our knowledge that links compromised cardiorespiratory fitness
with cognitive function in ADT-treated men, and poor
dual-task mobility with cognitive function in men with
PCa collectively. These findings reinforce the importance
of maintaining physical fitness and functional capacity for
cognitive health in men with PCa.
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